References
Adlard, P.A.; Bush, A.I. Metals and Alzheimer’s disease: how far have we come in the clinic? J. Alzheimers Dis. , 2018 , 62 , 1369-1379.
Alfahad, T.; Nath, A. Retroviruses and amyotrophic lateral sclerosis.Antiviral Res. , 2013 , 99 , 180-187.
Alquezar, C.; Salado, I.G.; de la Encarnación, A., Pérez, D.I.; Moreno, F.; Gil, C.; de Munain, A.L.; Martínez, A.; Martín-Requero, Á. Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegener. ,2016 , 11 , 36.
Ampornadai, K.; Rogers, M.; Watanabe, S.; Yamanaka, K.; O’Neill, P.M.; Hasnain, S.S. Novel selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis. EBioMedicine ,2020 , 59 , 102980.
Anzai, I.; Toichi, K.; Tokuda, E.; Mukaiyama, A.; Akiyama, S.; Furukawa, Y. Screening of drugs inhibiting in vitro oligomerization of Cu/Zn-superoxide dismutase with a mutation causing amyotrophic lateral sclerosis. Front. Mol. Biosci. , 2016 , 3 , 40.
Archbold, H.C.; Jackson, K.L.; Arora, A.; Weskamp, K.; Tank, E.M.; Li, X.; Miguez, R.; Dayton, R.D.; Tamir, S.; Klein, R.L.; Barmada, S.J. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci. Rep. ,2018 , 8 , 4606.
Ari, C.; Poff, A.M.; Held, H.E.; Landon, C.S.; Goldhagen, C.R.; Mavromates, N.; D’Agostino, D.P. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One ,2014 , 9 , e103526.
Auclair, J.R.; Boggio, K.J.; Petsko, G.A.; Ringe, D.; Agar, J.N. Strategies for stabilizing superoxide dismutase (SOD1), the destabilized in the most common form of familial amyotrophic lateral sclerosis.Proc. Natl. Acad. Sci. USA , 2010 , 107 , 21394-21399.
Audet, J.N.; Soucy, G.; Julien, J.P. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience , 2012 , 209 , 136-143.
Balendra, R.; Moens, TG.; Isaacs, A.M. Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies.EMBO Mol. Med. , 2017 , 7 , 853-855.
Barmada, S.J.; Serio, A.; Arjun, A. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. ,2014 , 10 , 677-685.
Benatar, M.; Wuu, J.; Andersen, P.M.; Atassi, N.; David, W.; Cudkowicz, M.; Schoenfeld, D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology ,2018 , 90 , e565-e574.
Blokhuis, A.M.; Groen, E.J.; Koppers, M.; van den Berg, L.H.; Pasterkamp, R.J. Protein aggregation in amyotrophic lateral sclerosis.Acta Neuropathol. , 2013 , 125 , 777-794.
Bose, P.; Tremblay, E.; Maois, C.; Narasimhan, V.; Armstrong, G.A.B.; Liao, M.; Parker, J.A.; Robitaille, R.; Wen, X.Y.; Barden, C.; Drapeau, P. The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis.Neurotherapeutics , 2019 , 16 , 1149-1166.
Boyd, J.D.; Lee, P.; Feiler, M.S.; Zauur, N.; Liu, M.; Concannon, J.; Ebata, A.; Wolozin, B.; Glicksman, M.A. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screen. , 2014 ,19 , 44-56.
Brown, R.H.; Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. , 2017 , 377 , 162-172.
Caccamo, A.; Shaw, D.M.; Guarino, F.; Messina, A.; Walker, A.W.; Oddo, S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. Hum. Mol. Genet. , 2015 , 24 , 4625-4635.
Cappella, M.; Ciotti, C.; Cohen-Tannoudji, M.; Biferi, M.G. Gene therapy for ALS-a perspective. Int. J. Mol. Sci. , 2019 ,20 , E4388.
Capper, M.J.; Wright, G.S.A.; Barbieri, L.; Luchinat, E.; Mercatelli, E.; McAlary. L.; Yerbury, J.J.; O’Neil, P.M.; Antonyuk, S.V.; Banci, L.; Hasnain, S.S. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat. Commun. , 2018 , 9 , 1693.
Cheah, B.C.; Kiernan. M.C. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs , 2010 , 13 , 911-920.
Chen, T.; Benmohamed, R.; Arvanites, A.C.; Ralay Ranaivo, H.; Morimoto, R.I.; Ferrante, R.J.; Watterson, D.M.; Kirsch, D.R.; Silverman, R.B. Arylsuflanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis.Bioorg. Med. Chem. , 2011 , 19 , 613-622.
Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R.I.; Kirsch, D.R.; Ferrante, R.J.; Silverman, R.B. ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J. Med. Chem. , 2012 , 55 , 515-527.
Cheng, C.W.; Lin. M.J.; Shen, C.K. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J. Neurogenet. , 2015 ,29 , 59-68.
Cheng, W.; Wang, S.; Mestre, A.A.; Fu, C.; Makarem, A.; Xian, F.; Hayes, L.R.; Lopez-Gonzalez, R.; Drenner, K.; Jiang, J.; Cleveland, D.W.; Sun, S. C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2α phosphorylation. Nat. Commun. ,2018 , 9 , 51.
Colombrita, C.; Zennaro, E.; Fallini, C. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. ,2009 , 111 , 1051-1061.
Congdon, E.E.; Wu, J.W.; Myeku, N.; Figueroa, Y.H.; Herman, M.; Marinec, P.S.; Gestwicki, J.E.; Dickey, C.A.; Yu, W.H.; Duff, K.E. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy ,2012 , 8 , 609-622.
Contestabile, A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr. Med. Chem. , 2011 , 18 , 5655-5665.
Contreras-Galindo, R.; Dube, D.; Fujinaga, K.; Kaplan, M.H.; Markovitz, D.M. Susceptibility of human endogenous retrovirus type K to reverse transcriptase inhibitors. J. Virol. , 2017 , 91 , e01309.
fCox, P.A.; Banack, S.A.; Murch, S.J. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA , 2003 , 100 , 13380-13383.
Crippa, V.; D’ Agostino, V.G.; Cristofani, R.; Rusmini, P.; Cicardi, M.E.; Messi, E.; Loffredo, R.; Pancher, M.; Piccolella, M.; Galbiati, M.; Meroni, M.; Cereda.; Carra, S.; Provenzani, A.; Poletti, A. Transcriptional induction of the heat shock protein B8 mediated the clearance of misfolded proteins responsible for motor neuron diseases.Sci. Rep. , 2016 , 6 , 22827.
Cudkowicz, M.E.; Titus, S.; Kearney, M.; Yu, H.; Sherman, A.; Schoenfeld, D.; Hayden, D.; Shui, A.; Brooks, B.; Conwit, R.; Felsenstein, D.; Greenblatt, D.J.; Keroack, M.; Kissel, J.T.; Miller, R.; Rosenfeld, J.; Rothstein, J.; Simpson, E.; Tolkoff-Rubin, N.; Zinman, L.; Shefner, J.M. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomized, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. ,2015 , 13 , 1083-1091.
Das, I.; Krzyzosiak, A.; Schneider, K.; Wrabetz, L.; D’ Antonio, M.; Barry, N.; Sigurdardottir, A.; Bertolotti, A. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit.Science , 2015 , 348 , 239-242.
DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; Kouri, N.; Wojtas, A.; Sengdy, P.; Hsiung, G.Y.; Karydas, A.; Seeley, W.W.; Josephs, K.A.; Coppola, G.; Geschwind, D.H.; Wszolek, Z.K.; Feldman, H.; Knopman, D.S.; Petersen, R.C.; Miller, B.L.; Dickson, D.W.; Boylan, K.B.; Graff-Radford, N.R.; Rademakers, R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron , 2011 , 72 , 245-256.
Diekstra, F.P.; van Vught, P.W.J.; van Rheenen, W.; Koppers, M.; Pasterkamp, R.J.; van Es, M.A.; Schelhaas, H.J.; de Visser, M.; Robberecht, W.; Van Damme, P.; Andersen, P.M.; van den Berg, L.H.; Veldink, J,H. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging , 2012 , 33 , 630.
Douville, R.; Liu, L.; Rothstein, J.; Nath, A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann. Neurol. , 2011 ,69 , 141-151.
Dupuis, L.; Dengler, R.; Heneka, M.T.; Meyer, T.; Zierz, S.; Kassubek, J.; Fischer, W.; Steiner, F.; Lindauer, E.; Otto, M.; Dreyhaupt, J.; Grehl, T.; Hermann, A.; Winkler, A.S.; Bogdahn, U.; Benecke, R.; Schrank, B.; Wessig, C.; Grosskreutz, J.; Ludolph, A.C.; GERP ALS Study Group. (2017) A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One , 2017 , 7 , e37885.
Egawa, N.; Kitaoka, S.; Tsukita, K.; Naitoh, M.; Takahashi, K.; Yamamoto, T.; Adachi, F.; Kondo, T.; Okita, K.; Asaka, I.; Aoi, T.; Watanabe, A.; Yamada, Y.; Morizane, A.; Takahashi, J.; Ayaki, T.; Ito, H.; Yoshikawa, K.; Yamawaki, S.; Suzuki, S.; Watanabe, D.; Hioki, H.; Kaneko, T.; Makioka, K.; Okamoto, K.; Takuma, H.; Tamaoka, A.; Hasegawa, K.; Nonaka, T.; Hasegawa, M.; Kawata, A.; Yoshida, M.; Nakahata, T.; Takahashi, R.; Marchetto, M.C.; Gage, F.H.; Yamanaka, S.; Inoue, H. Drug screening for ALS using patient-specific induced pluripotent stem cells.Sci. Transl. Med. , 2012 , 4 , 145ra104.
Fiala, M.; Mizwicki, M.T.; Weitzman, R.; Magpantay, L.; Nishimoto, N. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am. J. Neurodegener. Dis. , 2013 , 2 , 129-139.
Gianforcaro, A.; Hamadeh, M.J. Vitamin D as a potential therapy in amytrophic lateral sclerosis. CNS Neurosci. Ther. , 2014 ,20 , 101-111.
Goutman, S.A.; Savelieff, M.G.; Sakowski, S.A.; Feldman, E.L. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin. Investig. Drugs , 2019 ,28 , 525-543.
Gowing, G.; Dequen, F.; Soucy, G.; Julien, J.P. Absence of tumor necrosis factor-α does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. , 2006 ,26 , 11397-11402.
Graf, M.; Ecker, D.; Horowski, R.; Kramer, B.; Riederer, P.; Gerlach, M.; Hager, C.; Ludolph, A.C.; Becker, G.; Osterhage, J.; Jost, W.H.; Schrank, B.; Stein, C.; Kostopulos, P.; Lubik, S.; Wekwerth, K.; Dengler, R.; Troeger, M; Wuerz, A.; Hoge, A.; Schrader, C.; Schimke, N.; Krampfl, K.; Petri, S.; Zierz, S.; Eger, K.; Neudecker, S.; Traufeller, K.; Sievert, M.; Neundörfer, B.; Hecht, M.; German vitamin E/ALS Study Group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J. Neural. Transm. , 2005 , 112 , 649-660.
Griffiths, D.J. Endogenous retroviruses in the human genome sequence.Genome Biol. , 2001 , 2 , REVIEWS1017.
Groeneveld, G.J., Veldink, J.H.; van der Tweel, I.; Kalmijn, S.; Beijer, C.; de Visser M.; Wokke, J.H.J.; Franssen, H.; van den Berg, L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. , 2003 , 53 , 437-445
Guo, H.; Lai, L.; Butchbach, M.E.; Stockinger, M.P.; Shan, X.; Bishop, G.A.; Lin, C.L. Increased expression of the glial glutamate transporter EAAT2 modulates excitoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. , 2003 , 12 , 2519-2532.
Gurney, M.E.; Cutting, F.B.; Zhai, P.; Doble, A.; Taylor, C.P.; Andrus, P.K.; Hall, E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. , 1996 , 39 , 147-157.
Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science , 1994 , 264 , 1772-1775.
Han, Y.; Ripley, B.; Serada, S.; Naka, T.; Fujimoto, M. Interleukin-6 deficiency does not affect motor neuron disease caused by superoxide dismutase 1 mutation. PLOS One , 2016 , 11 , e0153399.
Hardiman, O.; Al-Chalabi, A.; Chio, A.; Corr, E.M.; Logroscino, G.; Robberecht, W.; Shaw, P.J.; Simmons, Z.; van den Berg, L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers , 2017 ,3 , 17071.
Hergesheimer, R.C.; Chami, A.A.; de Assis, D.R. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain , 2019 , 142 , 1176-1194.
Heyburn, L.; Hebron, M.L.; Smith, J.; Winston, C.; Bechara, J.; Li, Z.; Lonskaya, I.; Burns, M.P.; Harris, B.T.; Moussa, C.E. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. J. Neurochem. , 2016 , 139 , 610-623.
Hilton, J.B.; Mercer, S.W.; Lim, N.K.; Faux, N.G.; Buncic, G.; Beckman, J.S.; Roberts, B.R.; Donnelly, P.S.; White, A.R.; Crouch, P.J. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. , 2017 , 7 , 42292.
Hogg, M.C.; Halang, L.; Woods, I.; Coughlan, K.S.; Prehn, J.H.M. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph. Lateral Scler. Frontotemporal Degener. ,2018 , 19 , 438-445.
Imamura, K.; Izumi, Y.; Watanabe, A.; Tsukita, K.; Woltjen, K.; Yamamoto, T.; Hotta, A.; Kondo, T.; Kitaoka, S.; Ohta, A.; Tanaka, A.; Watanabe, D.; Morita, M.; Takuma, H.; Tamaoka, A.; Kunath, T.; Wray, S.; Furuya, H.; Era, T.; Makioka, K.; Okamoto, K.; Fujisawa, T.; Nishitoh, H.; Homma, K.; Ichijo, H.; Julien, J.P.; Obata, N.; Hosokawa, M.; Akiyama, H.; Kaneko, S.; Ayaki, T.; Ito, H.; Kaji, R.; Takahashi, R.; Yamanaka, S.; Inoue, H. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. ,2017 , 9 , eaaf3962.
Jaiswal, M.K. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. , 2019 , 39 , 733-748.
Jiang, J.; Zhu, Q.; Gendron, T.F.; Saberi, S.; McAlonis-Downes, M.; Seelman, A.; Stauffer, J.E.; Jafar-Nejad, P.; Drenner, K.; Schulte, D.; Chun, S.; Sun, S.; Ling, S.C.; Myers, B.; Engelhardt, J.; Katz, M.; Baughn, M.; Platoshyn, O.; Marsala, M.; Watt, A.; Heyser, C.J.; Ard, M.C.; De Muynck, L.; Daughrity, L.M.; Swing, D.A.; Tessarollo, L.; Jung, C.J.; Delpoux, A.; Utzschneider, D.T.; Hedrick, S.M.; de Jong, P.J.; Edbauer, D.; Van Damme, P.; Petrucelli, L.; Shaw, C.E.; Bennett, C.F.; Da Cruz, S.; Ravits, J.; Rigo, F.; Cleveland, D.W.; Lagier-Tourenne, C. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron , 2016 , 90 , 535-550.
Joardar, A.; Menzl, J.; Podolsky, T.C. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. Hum. Mol. Genet. , 2015 , 24 , 1741-1754.
Kalmar, B.; Edet-Amana, E.; Greensmith, L. Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. , 2012 , 13 , 378-392.
Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M.E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD193A mouse model of ALS. J. Neurochem. , 2008 , 102 , 339-350.
Kaneb, H.M.; Sharp, P.S.; Rahmani-Kondori, N.; Wells, J. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1G93A mouse model of ALS and is harmful in female mice.PLoS One , 2011 , 6 , e24189.
Kaplan, A.; Spiller, K.J.; Towne, C.; Kanning, K.C.; Choe, G.T.; Geber, A.; Akay, T.; Aebischer, P.; Henderson, C.E. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration.Neuron , 2014 , 81 , 333-348.
Karam, C.; Barrett, M.J.; Imperato, T.; MacGowan, D.J.L.; Scelsa, S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J. Clin. Neurosci. , 2013 ,20 , 1550-1553.
Kaufmann, P.; Thompson, J.L.; Levy, G.; Buchsbaum, R.; Shefner, J.; Krivickas, L.S.; Katz, J.; Rollins, Y.; Barohn, R.J.; Jackson, C.E.; Tiryaki, E.; Lomen-Hoerth, C.; Armon, C.; Tandan, R.; Rudnicki, S.A.; Rezania, K.; Sufit, R.; Pestronk, A.; Novella, S.P.; Heiman-Patterson, T.; Kasarskis, E.J.; Pioro, E.P.; Montes, J.; Arbing, R.; Vecchio, D.; Barsdorf, A.; Mitsumoto, H.; Levin, B.; QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.Ann. Neurol. , 2009 , 66 , 235-244.
Khosravi, B.; LaClair, K.D.; Riemenschneider, H.; Zhou, Q.; Frottin, F.; Mareljic, N.; Czuppa, M.; Farny, D.; Hartmann, H.; Michaelsen, M.; Arzberger, T.; Hartl, F.U.; Hipp, M.S.; Edbauer, D. Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD.EMBO J. , 2020 , 16 , e102811.
Kiaei, M.; Kipiani, K.; Calingasan, N.Y.; Wille, E.; Chen, J.; Heissig, B.; Rafii, S.; Lorenzl, S.; Beal, M.F. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. , 2007 , 205 , 74-81.
Kiaei, M.; Petri, S.; Kipiani, K.; Gardian, G.; Choi, D.K.; Chen, J.; Calingasan, N.Y.; Schafer, P.; Muller, G.W.; Stewart, C.; Hensley, K.; Beal, M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Aging ,2006 , 26 , 2467-2473.
Kieran, D.; Kalmar, B.; Dick, J.R.T.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. ,2004 , 10 , 402-405.
Kramer, N.J.; Haney, M.S.; Morgens, D.W.; Jovičić, A.; Couthouis, J.; Li, A.; Ousey, J.; Ma, R.; Bieri, G.; Tsui, K.; Shi, Y.; Hertz, N.T.; Tessier-Lavigne, M.; Ichida, J.K., Bassik, M.C.; Gitler, A.D. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat. Genet. , 2018 , 50 , 603-612.
Lange, D.J.; Shahbazi, M.; Silani, V.; Ludolph, A.C.; Weishaupt, J.H.; Ajroud-Driss, S.; Fields, K.G.; Remanan, R.; Appel, S.H.; Morelli, C.; Doretti, A.; Maderna, L.; Messina, S.; Weiland, U.; Marklund, S.L.; Andersen, P.M. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis with SOD1 mutations. Annals Neurol. , 2017 , 81 , 837-848.
Lehmer, C.; Oeckl, P.; Weishaupt, J.H.; Volk, A.E.; DiehlSchmid, J.; Schroeter, M.L.; Lauer, M.; Kornhuber, J.; Levin, J.; Fassbender, K.; Landwehrmeyer, B.; German Consortium for Frontotemporal Lobal Degeneration; Schludi, M.H.; Arzberger, T.; Kremmer, E.; Flatley, A.; Feederle, R.; Steinacker, P.; Weydt, P.; Ludolph, A.C.; Edbauer, D.; Otto, M. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD.EMBO Mol. Med. , 2017 , 9 , 859-868.
Lenglet, T.; Lacomblez, L.; Abitbol, J.L.; Ludolph, A.; Mora, J.S.; Robberecht, W.; Shaw, P.J.; Pruss, R.M.; Cuvier, V.; Meininger, V.; Mitotarget Study Group. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. ,2014 , 21 , 529-536.
Li, W.; Lee, M.H.; Henderson, L.; Tyagi, R.; Bachari, M.; Steiner, J.; Campanac, E.; Hoffman, D.A.; von Gelden, G.; Johnson, K.; Maric, D.; Morris, H.D.; Lentz, M.; Pak, K.; Mammen, A.; Ostrow, L.; Rothstein, J.; Nath, A. Human endogenous retrovirus-K contributes to motor neuron disease. Sci. Transl. Med. , 2015 , 7 , ra153.
Liachko, N.F.; McMillan, P.J.; Guthrie, C.R.; Bird, T.D.; Leverenz, J.B.; Kraemer, B.C. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann. Neurol. ,2013 , 74 , 39-52.
Libonati, L.; Onesti, E.; Gori, M.C.; Ceccanti, M.; Cambieri, C.; Fabbri, A.; Frasca, V.; Inghilleri, M. Vitamin D in amyotrophic lateral sclerosis. Funct. Neurol. , 2017 , 32 , 35-40.
Limpert, A.S.; Mattmann, M.E., Cosford, N.D.P. Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis. Beilstein J. Org. Chem. , 2013 , 9 , 717-732.
Ling, K.K.; Jackson, M.; Alkam, D.; Liu, D.; Allaire, N.; Sun, C.; Kiaei, M.; McCampbell, A.; Rigo, F. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiol. Aging , 2018 ,114 , 174-183.
Liu, C.; Hong, K.; Chen, H.; Niu, Y.; Duan, W.; Liu, Y.; Duan, W.; Liu, Y.; Ji, Y.; Deng, B.; Li, Y.; Li, Z.; Wen, D.; Li, C. Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis. Biol. Chem. , 2019 , 400 , 651-661.
Lopez-Lopez, A.; Gamez, J.; Syriani, E.; Morales, M.; Salvado, M.; Rodriguez, M.J.; Ma, N.; Vidal-Taboada, J.M. CXC3R1 is a modifying gene of survival and progression in amyotrophic laterals sclerosis.PLoS One , 2014 , 9 , e96528.
Lougheed, R.; Turnbul, J. Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS One ,2011 , 6 , e23141.
Macchi, Z.; Wang, Y.; Moore, D.; Katz, J.; Saperstein, D.; Walk, D.; Simpson, E.; Genge, A.; Bertorini, T.; Fernandes, J.A.; Swenson, A.; Elman, L.; Dimachkie, M.; Herbelin, L.; Miller, J.; Lu, J.; Wilkins, H.; Swerdlow, R.H.; Statland, J.; Barohn, R.; Western ALS (WALS) Rasagiline Study Group. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotroph. Lateral Scler. Frontotemporal Degener. , 2015 , 16, 345-352.
Mandrioli, J.; Crippa, V.; Cereda, C.; Bonetto, V.; Zucchi, E.; Gessani, A.; Ceroni, M.; Chio, A.; D’ Amico, R.; Monsurrò, M.R.; Riva, N.; Sabatelli, M.; Silani, V.; Simone, I.L.; Sorarù, G.; Provenzani, A.; D’ Agostino, V.G.; Carra, S.; Poletti, A. Proteostasis and ALS: protocol for a phase II, randomized, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open , 2019 , 9 , e028486.
Mangelsdorf, I.; Walach, H.; Mutter, J. Healing of amyotrophic lateral sclerosis: a case report. Complement Med. Res. , 2017 ,24 , 175-181.
Marrone, L.; Drexler, H.C.A.; Wang, J.; Tripathi, P.; Distler, T.; Heisterkamp, P.; Anderson, E.N.; Kour, S.; Moraiti, A.; Maharana, S.; Bhatnagar, R.; Belgard, T.G.; Tripathy, V.; Kalmbach, N.; Hosseinzabeh, Z.; Crippa, V.; Abo-Rady, M.; Wegner, F.; Poletti, A.; Troost, D.; Aronica, E.; Busskamp, V.; Weis, J.; Pandey, U.B.; Hyman, A.A.; Alberti, S.; Goswami, A.; Sterneckert, J. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. , 2019 ,138 , 67-84.
Matthews, R.T.; Yang, L.; Browne, S.; Baik, M.; Beal, M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA ,1998 , 95 , 8892-8897.
Mayer, J.; Harz, C.; Sanchez, L.; Pereira, G.C.; Maldener, E.; Heras, S.R.; Ostrow, L.W.; Ravits, J.; Batra, R.; Meese, E.; García-Pérez, J.L.; Goodier, J.L. Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins. Mol. Neurodegener. , 2018 , 13 , 39.
Miquel, E.; Cassina, A.; Martínez-Palma, L.; Bolatto, C.; Trías, E.; Gandelman, M.; Radi, R.; Barbeito, L.; Cassina, P. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motol performance in inherited amyotrophic lateral sclerosis.PLoS One , 2012 , 7 , e34776.
Mitropoulos, K.; Katsila, T.; Patrinos, G.P.; Pampalakis, G. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis. OMICS , 2018 ,22 , 52-64.
Monson, C.S.; Banack, S.A.; Cox, P.A. Conservation implications of Chamorro consumption of flying foxes as a possible cause of amyotrophic lateral sclerosis-parkinsonism dementia complex in Guam. Conserv. Biol. , 2003 , 17 , 678-686.
Mori, K.; Arzberger, T.; Grässer, F.A.; Gijselinck, I.; May, S.; Rentzsch, K.; Weng, S.M.; Schludi, M.H.; van der Zee, J.; Cruts, M.; Van Broeckhoven, C.; Kremmer, E.; Kretzschmar, H.A.; Haass, C.; Edbauer, D. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. , 2013b , 126 , 881-893.
Mori, K.; Weng, S.M.; Arzberger, T.; May, S.; Rentzsch, K.; Kremmer, E.; Schmid, B.; Kretzschmar, H.A.; Cruts, M.; Van Broeckhoven, C.; Haass, C.; Edbauer, D. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science , 2013a ,339 , 1335-1338.
Moujalled, D.; James, J.L.; Parker, S.J.; Lidgerwood, G.E.; Duncan, C.; Meyerowitz, J.; Nonaka, T.; Hasegawa, M.; Kanninen, K.M.; Grubman, A.; Liddell, J.R.; Crouch, P.J.; White, A.R. Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress. PLoS One , 2013 , 8 , e67433.
Neumann, M.; Sampathu. D.M.; Kwong, L.K.; Truax, A.C.; Micsenyi, M.C.; Chou, T.T. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science2006 ,314 , 130-133.
Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. , 2009 ,220 , 191-197.
Noberini, R.; Koolpe, M.; Peddibhotla, S.; Dahl, R.; Su, Y.; Cosford, N.D.P.; Roth, G.P.; Pasquale, E.B. Small molecules can selectively inhibit ephrin bind EphA4 and EphA2 receptors. J. Biol. Chem. ,2008 , 283 , 29461-29472.
Paganoni, S.; Macklin, E.A.; Hendrix, S.; Berry, J.D.; Elliott, M.A.; Maiser, S.; Karam, C.; Caress, J.B.; Owegi, M.A.; Quick, A.; Wymer, J.; Goutman, S.A.; Heitzman, D.; Heiman-Patterson, T.; Jackson, C.E.; Quinn, C.; Rothstein, J.D.; Kasarskis, E.J.; Katz, J.; Jenkins, L.; Ladha, S.; Miller, T.M.; Scelsa, S.N.; Vu, T.H.; Fournier, C.N.; Glass, J.D.; Johnson, K.M.; Swenson, A.; Goyal, N.A.; Pattee, G.L.; Andres, P.L.; Babu, S.; Chase, M.; Dagostino, D.; Dickson, S.P.; Ellison, N.; Hall, M.; Hendrix, K.; Kittle, G.; McGovern, M.; Ostrow, J.; Pothier, L.; Randall, R.; Shefner, J.M.; Sherman, A.V.; Tustison, E.; Vigneswaran, P.; Walker, J.; Yu, H.; Chan, J.; Wittes, J.; Cohen, J.; Klee, J.; Leslie, K.; Tanzi, R.E., Gilber, W.; Yeramian, P.D.; Schoenfeld, D.; Cudkowicz, M.E. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. New Engl. J. Med. , 2020 ,383 , 919-930.
Palomo, V., Tosat-Bitrian, C.; Nozal, V.; Nagaraj, S.; Martin-Requero, A.; Martinez, A. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chem. Neurosci. , 2019 , 10 , 1183-1196.
Pampalakis, G.; Mitropoulos, K.; Xiromerisiou, G.; Dardiotis, E.; Deretzi, G.; Anagnostouli, M.; Katsila, T.; Rentzos, M.; Patrinos, G.P. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis. Hum. Mutat. , 2019 , 40 , 361-373.
Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N.Y.; Szeto, H.H.; Beal, M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. , 2006 ,98 , 1141-1148.
Polymenidou, M.; Lagier-Tourenne, C.; Hutt, K.R.; Bennett, C.F.; Cleveland, D.W.; Yeo, G.W. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res 1462: 3-15.
Posa D, Martínez-González L, Bartolomé F, Nagaraj S, Porras G, Martínez A, Martín-Requero Á. (2019) Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients.Mol. Neurobiol. , 2012 , 56 , 2424-2432.
Renton, A.E.; Majounie, E.; Waite, A.; Simón-Sánchez, J.; Rollinson, S.; Gibbs, J.R.; Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; Kalimo, H.; Paetau, A.; Abramzon, Y.; Remes, A.M.; Kaganovich, A.; Scholz, S.W.; Duckworth, J.; Ding, J.; Harmer, D.W.; Hernandez, D.G.; Johnson, J.O.; Mok, K.; Ryten, M.; Trabzuni, D.; Guerreiro, R.J.; Orrell, R.W.; Neal, J.; Murray, A.; Pearson, J.; Jansen, I.E.; Sondervan, D.; Seelaar, H.; Blake, D.; Young, K.; Halliwell, N.; Callister, J.B.; Toulson, G.; Richardson, A.; Gerhard, A.; Snowden, J.; Mann, D.; Neary, D.; Nalls, M.A.; Peuralinna, T.; Jansson, L.; Isoviita, V.M.; Kaivorinne, A.L.; Hölttä-Vuori, M.; Ikonen, E.; Sulkava, R.; Benatar, M.; Wuu, J.; Chiò, A.; Restagno, G.; Borghero, G.; Sabatelli, M; ITALSGEN Consortium; Heckerman, D.; Rogaeva, E.; Zinman, L.; Rothstein, J.D.; Sendtner, M.; Drepper, C.; Eichler, E.E.; Alkan, C.; Abdullaev, Z.; Pack, S.D.; Dutra, A.; Pak, E.; Hardy, J.; Singleton, A.; Williams, N.M.; Heutink, P.; Pickering-Brown, S.; Morris, H.R.; Tienari, P.J.; Traynor, B.J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron ,2011 , 72 , 257-268.
Roberts, B.R.; Lim, N.K.H.; McAllum, E.J.; Donnely, P.S.; Hare, D.J.; Doble, P.A.; Turner, B.J.; Price, K.A.; Lim, S.C.; Paterson, B.M.; Hickey, J.L.; Rhoads, T.W.; Williams, J.R.; Kanninen, K.M.; Hung, L.W.; Liddell, J.R.; Grubman, A.; Monty, J.F.; Llanos, R.M.; Kramer, D.R.; Mercer, J.F.B.; Bush, A.I.; Masters, C.L.; Duce, J.A.; Li, Q.X.; Beckman, J.S.; Barnham, K.J.; White, A.R.; Crouch, P.J. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. , 2014 ,34 , 8021-8031.
Roos, P.M.; Vesterberg, O.; Syversen, T.; Flaten, T.P.; Nordberg, M. Metal concentrations in cerebrospinal fluid and blood plasma form patients with amyotrophic lateral sclerosis. Biol. Trace Elem. Res.,2014 , 151 , 159-170.
Rösener, M.; Hahn, H.; Kranz, M.; Heeney, J.; Rethwilm, A. Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. J. Med. Virol.1998 ,48 , 222-226.
Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Hoberg, M.D.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fischer, P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature , 2005 , 433 , 73-77.
Rue, L.; Timmers, M.; Lenaerts, A.; Smolders, S.; Poppe, L.; de Boer, A.; Van Den Bosch, L.; Van Damme, P.; Robberecht, W.; Lemmens, R. Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. Sci. Rep. , 2019 ,9 , 14112.
Ryu, H.H.; Jun, M.H.; Min, K.J.; Jang, D.J.; Lee, Y.S.; Kim, H.K. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. Neurobiol. Aging ,2014 , 35 , 2822-2831.
Salado, I.G.; Redondo, M.; Bello, M.L. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J. Med. Chem. , 2014 , 57 , 275-2772.
Simone, R.; Balendra, R.; Moens, T.G.; Preza, E.; Wilson, K.M.; Heslegrave, A.; Woodling, N.S.; Niccoli, T.; Gilbert-Jaramillo, J.; Abdelkarim, S.; Clayton, E.L.; Clarke, M.; Konrad, M.T.; Nicoll, A.J.; Mitchell, J.S.; Calvo, A.; Chio, A.; Houlden, H.; Polke, J.M.; Ismail, M.A.; Stephens, C.E.; Vo, T.; Farahat, A.A.; Wilson, W.D.; Boykin, D.W.; Zetterberg, H.; Partridge, L.; Wray, S.; Parkinson, G.; Neidle, S.; Patani, R.; Fratta, P.; Isaacs, A.M. G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo.EMBO Mol. Med. , 2018 , 10 , 22-31.
Smith, L.G. Improvement of patient with amyotrophic laterals sclerosis given ceftriaxone. Lancet , 1992 , 339 , 1417.
Soo, K.Y.; Halloran, M.; Sundaramoorthy, V.; Parakh, S.; Toth, R.P.; Southam, K.A.; McLean, C.A., Lock, P.; King, A.; Farg, M.A.; Atkin, J.D. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. , 2015 , 130 , 679-697.
Spiller, K.J.; Khan, T.; Dominique, M.A.; Restrepo, C.R.; Cotton-Samuel, D.; Levitan, M.; Jafar-Nejad, P.; Zhang, B.; Soriano, A.; Rigo, F.; Trojanowski, J.Q.; Lee, V.M. Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiol. Dis. , 2019 , 124 , 133-140.
Staats, K.A.; Sea, H.C.; Sahimi, A.; Wang, Y.; Koutsodendris, N.; Lin, S.; Kim, D.; Chang, W.H.; Gray, K.A.; Shi, Y.; Li, Y.; Chateau, M.; Vangoor, V.R.; Senthilkumar, K.; Pasterkamp, R.J.; Cannon, P.; Zlokovic, B.V.; Ichida, J.K. Small molecule inhibition of PIKFYVE kinase rescues gain- and loss-of-function C9ORF72 ALS/FTD disease processes in vivo.bioRxiv2019 , 685800.
Stommel, E.W.; Cohen, J.A.; Fadul, C.E.; Cogbill, C.H.; Graber, D.J.; Kingman, L.; Mackenzie, T.; Channon Smith, J.Y.; Harris, B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler. ,2009 , 10 , 5-6.
Su, X.W.; Nandar, W.; Neely, E.B.; Simmons, Z.; Connor, J.R. Statins accelerate disease progression and shorten survival in SOD1 mice.Muscle Nerve , 2016 , 54 , 284-291.
Su, Z.; Zhang, Y.; Gendron, T.F.; Bauer, P.O.; Chew, J.; Yang, W.Y.; Fostvedt. E.; Jansen-West, K.; Belzil, V.V.; Desaro, P.; Johnston, A.; Overstreet, K.; Oh, S.Y.; Todd, P.K.; Berry, J.D.; Cudkowicz, M.E.; Boeve, B.F.; Dickson, D.; Floeter, M.K.; Traynor, B.J.; Morelli, C.; Ratti, A.; Silani, V.; Rademakers, R.; Brown, R.H.; Rothstein, J.D.; Boylan, K.B.; Petrucelli, L.; Disney, M.D. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron2014 , 83 , 1043-1050.
Sunyach, C.; Michaud, M.; Arnoux, T.; Bernard-Marissal, N.; Aebischer, J.; Latyszenok, V.; Gouarné, C.; Raoul C; Pruss, R.M.; Bordet, T.; Pettmann, B. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.Neuropharmacology , 2012 , 62 , 2346-2352.
Swinnen, B.; Robberecht, W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. , 2014 , 10 , 661-670.
Tian, K.W.; Jiang, H.; Wang, B.B.; Zhang, F.; Han, S. Intravenous injection of l-BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson-dementia complex. Toxicol. Res. (Camb) , 2015 , 5 , 79-96.
Trippier, P.C.; Zhao, K.T.; Fox, S.G.; Schiefer, I.T.; Benmohamed, R.; Moran, J.; Kirsch, D.R.; Morimoto, R.I.; Silverman, R.B. Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. ACS Chem. Neurosci. , 2014 , 5 , 823-829.
Trojsi, F.; Siciliano, M.; Passaniti, C.; Bisecco, A.; Russo, A.; Lavorgna, L.; Esposito, S.; Ricciardi, D.; Monsurrò, M.R.; Tedeschi, G.; Santangelo, G. Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS). Eur. J. Clin. Nutr. , 2020 , 74 , 167-175.
Tsuburaya, N.; Homma, K.; Higuchi, T.; Balia, A.; Yamakoshi, H.; Shibata, N.; Nakamura, S.; Nakagawa, H.; Ikeda, S.; Umezawa, N.; Kato, N.; Yokoshima, S.; Shibuya, M.; Shimonishi, M.; Kojima, H.; Okabe, T.; Nagano, T.; Naguro, I.; Imamura, K.; Inoue, H.; Fujisawa, T.; Ichijo, H. A small-molecule inhibitor of SOD1-Derlin 1 ameliorates pathology in an ALS mouse model. Nat. Commun. , 2018 , 9 , 2668.
Tyagi, R.; Li, W.; Parades, D.; Bianchet, M.A.; Nath, A. Inhibition of human endogenous retrovirus-K by antiretroviral drugs.Retrovirology , 2017 , 14 , 21.
Vaccaro, A.; Patten, S.A.; Ciura, S.; Maios, C.; Therrien, M.; Drapau, P.; Kabashi, E.; Parker, J.A. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio .PLOS One , 2012 , 7 , e42117.
Van Eijk, R.P.A.; Eijkemans, M.J.C.; Nikolakopoulos, S.; Jansen, M.D.; Westeneng, H.J.; van Eijk, K.R.; van der Spek, R.A.A.; van Vugt, J.J.F.A.; Piepers, S.; Groeneveld, G.J.; Veldink, J.H.; van den Berg, L.H.; van Es, M.A. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J. ,2019 , 20 , 220-226.
Van Eijk, R.P.A.; Jones, A.R.; Sproviero, W.; Shatunov, A.; Shaw, P.J.; Leigh, P.N.; Young, C.A.; Shaw, C.E.; Mora, G.; Mandrioti, J.; Borghero, G.; Volanti, P.; Diekstra, F.P.; van Rheenen, W.; Verstraete, E.; Eijkemans, M.J.C.; Veldink, J.H.; Chio, A.; Al-Chalabi, A.; van den Berg, L.H.; van Es, M.A.; For UKMND-LiCALS and LITALS study group. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology , 2017 , 89 , 1915-1922.
Van Hoecke, A.; Schoonaert, L.; Lemmens, R.; Timmers, M.; Staats, K.A.; Laird, A.S.; Peeters, E.; Philips, T.; Goris, A.; Dubois, B.; Andersen, P.M.; Al-Chalabi, A.; Thinjs, V.; Turnley, A.M.; van Vught, P.W.; Veldink, J.H.; Hardiman, O.; Van Den Bosch. L.; Gonzalez-Perez, P.; Van Damme, P.; Brown, JR. R.H.; van den Berg, L.H.; Robberecht, W. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. , 2012 , 18 , 1418-1422.
Vidal-Taboada, J.M.; Pugliese, M.; Salvadó, M.; Gámez, J.; Mahy, N.; Rodríguez, M.J. KATP channel expression and genetic polymorphisms associated with progression and survival in amyotrophic lateral sclerosis. Mol. Neurobiol. , 2018 , 55 , 7962-7972.
Waibel, S.; Reuter, A.; Malessa, S.; Blaugrund, E.; Ludolph, A.C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol. , 2004 , 251 , 1080-1084.
Wang, I.F.; Guo, B.S.; Liu, Y.C. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl. Acad. Sci. USA ,2012 , 109 , 15024-15029.
Wang, Z.F.; Ursu, A.; Childs-Disney, J.L.; Guertler, R.; Yang, W.Y.; Bernat, V.; Rzuczek, S.G.; Fuerst, R.; Zhang, Y.J.; Gendron, T.F.; Yildirim, I.; Dwyer, B.G.; Rice, J.E.; Petrucelli, L.; Disney, M.D. The Hairpin Form of r(G(4)C(2))(exp) in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules.Cell Chem. Biol. , 2019 , 26 , 179-190.e12.
Westarp, M.E.; Bartmann, P.; Rossler, J.; Geiger, E.; Westphal, K.P.; Schreiber, H.; Fuchs, D.; Westarp, M.P.; Kornhuber, H.H. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis.Neuroreport , 1993 , 4 , 819-822.
Wilkins, H.M.; Morris, J.K. New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. Curr. Pharm. Des. ,2017 , 23 , 731-752.
Wosiski-Kuhn, M.; Robinson, M.; Strupe, J.; Arounleut, P.; Martin, M.; Caress, J.; Cartwright, M.; Bower, R.; Cudkowicz, M.; Langefeld, C.; Hawkins, G.A.; Milligan, C. IL6 receptor 358Ala variant and trans-signaling disease modifiers in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. , 2019 ,6 , e631.
Wu, B., De, S.K.; Kulinich, A.; Salem, A.F.; Koeppen, J.; Wang, R.; Barile, E.; Wang, S.; Zhang, D.; Ethell, I.; Pellecchia, M. Potent and Selective EphA4 Agonists for the Treatment of ALS. Cell Chem. Biol. , 2017 , 24 , 293-305.
Xia, Q.; Wang, H.; Hao, Z. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J. ,2016 , 35 , 121-142.
Xiao, S.; Sanelli, T.; Dib, S. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol. Cell. Neurosci., 2011 ,47 , 167-180.
Yanagi, K.S.; Wu, Z.; Amaya, J.; Chapkis, N.; Duffy, A.M.; Hajdarovic, K.; Held, A.; Mathur, A.D.; Russo, K.; Ryan, V.H.; Steinert, B.L.; Whitt, J.P.; Fallon, J.R.; Fawzi, N.L.; Lipscombe, D.; Reenan, R.A.; Wharton, K.A.; Hart, A.C. Meta-analysis of genetic modifiers reveals candidate dysregulated pathways in Amyotrophic Lateral Sclerosis.Neuroscience , 2019 , 396 , A3-A20.
Zamiri, B.; Reddy, K.; Macgregor, R.B. Jr.; Pearson, C.E. TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. , 2014 , 289 , 4653-4659.
Zarogoulidis, P.; Lampaki, S.; Turner, J.F. mTOR pathway: A current, up-to-date mini-review. Oncol. Lett. , 2014 , 8 , 2367-2370.
Zhang, X., Li, L.; Chen, S.; Yang, D.; Wang, Y.; Zhang, X.; Wang, Z.; Le, W. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.Autophagy , 2011 , 7 , 412-25.
Zhang, Y.; Zhao, K.T.; Fox, S.G.; Kim, J.; Kirsch, D.R.; Ferrante, R.J.; Morimoto, R.I.; Silverman, R.B. Tertiary amine pyrazolones and their salts as inhibitors of mutant superoxide dismutase 1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J. Med. Chem. , 2015 , 58 , 5942-5949.
Zhang, Y.J.; Jansen-West, K.; Xu, Y.F.; Gendron, T.F.; Bieniek, K.F.; Lin, W.L.; Sasaguri, H.; Caulfield, T.; Hubbard, J.; Daughrity, L.; Chew, J.; Belzil, V.V.; Prudencio, M.; Stankowski, J.N.; Castanedes-Casey, M.; Whitelaw, E.; Ash, P.E.; DeTure, M.; Rademakers, R.; Boylan, K.B.; Dickson, D.W.; Petrucelli, L. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. , 2014 , 128 , 505-524.
Zhou, Q.; Mareljic, N.; Michaelsen, M.; Parhizkar, S.; Heindl, S.; Nuscher, B.; Farny, D.; Czuppa, M.; Schludi, C.; Graf, A.; Krebs, S.; Blum, H.; Feederle, R.; Roth, S.; Haass, C.; Arzberger, T.; Liesz, A.; Edbauer, D. Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol. Med. ,2020 , 12 , e10919.
Zinman, L.; Sadeghi, R.; Gawel, M.; Patton, D.; Kiss, A. Are statin medications safe in patients with ALS? Amyotroph. Lateral Scler. ,2008 , 9 , 223-228.
Zoing, M.C.; Burke, D.; Pamphlett, R. Riluzole therapy for motor neurone disease: An early Australian experience (1996–2002). J. Clin. Neurosci. , 2006 , 13 , 78-83.
Zou, Z.Y.; Zhou, Z.R.; Che, C.H.; Liu, C.Y.; He, R.L.; Huang, H.P. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry ,2017 , 88 , 540-549
Zu, T.; Guo, S.; Bardhi, O.; Ryskamp, D.A.; Li, J.; Tusi, S.K.; Engelbrecht, A.; Klippel, K.; Chakrabarty, P.; Nguyen, L.; Golde, T.E.; Sonenberg, N.; Ranum, L.P.W. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9ORF72 ALS/FTD mice. Proc. Natl. Acad. Sci. USA , 2020 , 117 , 18591-18599.